Opens in a new tab

Advanced Bionics v MED-EL Elektromedizinische Geräte Gesellschaft m.b.H. (CoA, ORD_42780/2024, 5 September 2024)

Date5 September 2024
CourtCoA
DivisionLuxembourg (LU)
Type of actionAppeal RoP220.2
Registry referenceAPL_12739/2024 · ORD_42780/2024
PartiesAdvanced Bionics Sarl , Advanced Bionics AG, Advanced Bionics GmbH v. MED-EL Elektromedizinische Geräte Gesellschaft m.b.H.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 5 September 2024 (UPC_CoA_106/2024, APL_12739/2024), the Court of Appeal (K. Grabinski, presiding, P. Blok, rapporteur, E. Germano) dismissed Advanced Bionics’ appeal against the Mannheim Local Division’s order of 22 February 2024 refusing to transfer to the Central Division, for joint hearing with the revocation action filed on 27 September 2023, the infringement action on EP 4 074 373 brought by MED-EL on 2 November 2023. The order lays down two principles on the allocation of cases between divisions.

Question

Does joinder for connection under Rule 340 RoP, or Art. 33 UPCA, allow an infringement action to be transferred from a local division to the Central Division without the parties’ consent?

Decision

No. Rule 340 RoP cannot lead to a transfer outside the cases provided for in Art. 33 UPCA, which prevails over the Rules of Procedure under Art. 41(1) UPCA and Rule 1.1 RoP, Rule 340 itself requiring Art. 33 to be observed (paragraph 8). Art. 33(3)(c) UPCA allows an infringement action together with a counterclaim for revocation to be referred only with the parties’ agreement, and Art. 33(5) read with Art. 33(3) does not allow a transfer without consent either (paragraph 9). As MED-EL expressly objected, transfer was ruled out (paragraph 10). The risk of divergent claim construction does not alter this: the revocation action, which is further advanced, is likely to be decided first, the Mannheim panel can take it into account, and the defendants can draw its attention to the construction advanced by MED-EL before the Central Division (paragraph 11).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts. 33(3) and (5) and 41(1)
Rules of Procedure
Rules 1.1 and 340

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: UPC Court of Appeal, Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: UPC Appeals: What the Numbers Show, Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Appeal RoP220.2
Outcome (Dhenne Avocats summary)
La cour d'appel juge que ni la règle 340 ni l'article 33 de l'Accord ne permettent de renvoyer une action en contrefaçon d'une division locale à la division centrale sans l'accord des parties, et rejette l'appel.
Appeal
Decision of the Court of Appeal.
Instance
Court of Appeal decision.

Patents mentioned

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 074 373
Mri-safe disk magnet for implants
recorded proprietor: MED EL Elektromedizinische Geraete GmbH
Mentioned in the analysis (role not qualified)
Also mentioned in 9 other decision(s): Advanced Bionics v MED-EL Elektromedizinische Geräte (CFI, 26 December · MED-EL Elektromedizinische Geräte v Zhejiang Nurotron Biotechnology (C · MED-EL Elektromedizinische Geräte v Zhejiang Nurotron Biotechnology (C · Advanced Bionics v MED-EL Elektromedizinische Geräte (CoA, 3 July 2025 · MED-EL v Advanced Bionics (CFI, 28 May 2025) · Advanced Bionics v MED-EL Elektromedizinische Geräte Gesellschaft m.b. · MED-EL Elektromedizinische Geräte Gesellschaft m.b.H. v Advanced Bioni · Advanced Bionics v MED-EL Elektromedizinische Geräte (CFI, 15 April 20
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.